Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
Fidelity (FHLC) vs. iShares (IXJ): Which Healthcare ETF Delivers Better Value?
26.06.2026 11:40
Compare global reach to domestic focus as these two funds reveal key differences in cost, risk, and portfolio makeup for healthcare investors.
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
26.06.2026 11:16
Eli Lilly and Company (NYSE: LLY) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, for the treatment of adults with chronic lymphocytic leukemia (CLL) across all lines of therapy and regardless of prior BTK inhibitor treatment. Following this positive opinion, the application is now referred to the European Commission f
Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy
26.06.2026 10:27
Amid the debut of positive Phase I data, the biotech will push its lead asset further down the clinical pipeline in endometriosis and pattern hair loss.
Absci (ABSI) Is Up 37.8% After ABS-201 Data And Equity Raise - Has The Bull Case Changed?
26.06.2026 08:06
Earlier this week, Absci Corporation reported encouraging interim Phase 1 data from its HEADLINE trial of ABS-201 for androgenetic alopecia, showing favorable safety, an estimated half-life of at least 65 days, and progression into a multiple ascending dose stage. On the heels of these results, Absci also completed a roughly US$100.00 million follow-on equity offering backed by Eli Lilly & Company and other institutional investors, underscoring external confidence in the ABS-201 program...
Eli Lilly (LLY) Acquires Centessa Pharmaceuticals to Advance Orexin Receptor 2 Agonists
26.06.2026 08:06
Eli Lilly and Company (NYSE:LLY) is one of the best stocks for beginners to buy now. On June 24, Eli Lilly completed its acquisition of Centessa Pharmaceuticals, aiming to advance the development of orexin receptor 2 agonists. This new class of medicine is designed to treat narcolepsy and other sleep-wake disorders by targeting the brain’s […]
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying
26.06.2026 07:30
Cabaletta Bio (CABA) CAR-T for autoimmune disease: EULAR 2026 data, $2.90 entry, $150M raise, 2H27 BLA path, and upside potentialâread now.
InSilico Is on a Mission: Be No. 1 in China, Create ‘God Drug’ With AI
26.06.2026 06:47
The pharma company, the first to use generative AI to develop a drug that reached clinical trials, is betting longevity treatments will fuel its next phase of growth.
Nancy Pelosi Stock Tracker Flags Eli Lilly, Nokia After Trump Praise: ‘Keep An Eye On These Two’
26.06.2026 02:31
The Nancy Pelosi Stock Tracker account on Wednesday spotlighted Eli Lilly & Co. and Nokia Oyj after President Donald Trump praised the companies’ U.S. investment plans during a rally in Pennsylvania. ‘Keep An Eye’ Trump said Eli Lilly will invest...
Eli Lilly & Co (NYSE:LLY) Screens as a Top Growth Stock with a Strong Technical Breakout Setup
25.06.2026 08:50
Discover how Eli Lilly (LLY) combines explosive growth and strong technical setup. A deep-dive into this top-rated stock's breakout potential.
Eli Lilly and Company (LLY) – Among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors
25.06.2026 04:16
Eli Lilly and Company (NYSE:LLY) is included among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors. On June 23, Reuters reported that Eli Lilly and Company (NYSE:LLY) expects to launch its weight-loss pill in Europe and the UK in the second half of 2026 or early 2027. The company plans to target the out-of-pocket […]
The Bull Case For Eli Lilly (LLY) Could Change Following New Multi‑Target R&D Alliances With Biotechs
25.06.2026 01:15
In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones for Abbisko and up to US$770 million for BioArctic, alongside royalties on any future product sales. These alliances, paired with Lilly’s ongoing advances in obesity, oncology, and neurodegeneration programs, underline how external partnerships are being used to broaden its pipeline beyond its...
LLY Stock Rides Trump Spotlight: President Touts Eli Lilly’s $3.5B Factory As Weight-Loss Pill Plans Go Global
24.06.2026 03:27
Trump said the new “state-of-the-art” facility would create over 1,000 jobs.
Adding Eli Lilly’s R&D Chief to the Board Might Change The Case For Investing In Illumina (ILMN)
24.06.2026 01:12
Illumina, Inc. recently expanded its Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories, as an independent director effective June 16, 2026. His background in drug discovery, clinical development, and precision medicine across cardiometabolic, immunology, and neuroscience fields aligns closely with Illumina’s push into clinical genomics and multiomics. We’ll now examine...
Abbisko Therapeutics Deepens R&D Collaboration with Lilly
24.06.2026 01:00
Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collaboration and license agreement with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company. Under the agreement, the two companies will collaborate on the discovery and development of innovative medicines across multiple targets, advancing novel drug candidates with global potential.
Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?
23.06.2026 14:34
The GLP-1 drug market is massive and still growing fast. Investing in a promising growth stock in the space could lead to significant returns.
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
23.06.2026 13:05
Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky brings extensive experience in drug discovery, clinical development and translational medicine, which are areas directly relevant to Illumina's work advancing genomics and multiomics platforms.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
23.06.2026 13:00
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
ŌURA and LillyDirect to Expand Support for People Using GLP-1 Therapies with New Tools and Savings Options
23.06.2026 13:00
SAN FRANCISCO & INDIANAPOLIS, June 23, 2026--ŌURA, maker of the world’s most trusted smart ring, Oura Ring, and LillyDirect, Eli Lilly and Company’s digital health platform designed to connect people living with chronic conditions to the care, support, and prescribed medicines they need, today announced a collaboration enabling savings on the Oura Ring sizing kit. The companies will coordinate to improve access to prescribed treatment and integrated behavioral support tools that complement presc
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
23.06.2026 12:05
Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today a
TRIMTECH Therapeutics Brings Total Seed Round to $47M with Additional Investment of $14M to Further Develop TRIMTAC and TRIMGLUE Targeted Protein Degradation Portfolio
23.06.2026 09:37
CAMBRIDGE, England, June 23, 2026--TRIMTECH Therapeutics (TRIMTECH or the Company), a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has raised an additional $14 million in seed funding, bringing the total for the round to $47 million (£35 million). The financing was led by Johnson & Johnson’s corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.